6 results about "Human b cell" patented technology

A continuous directed evolution platform in human B cell lines (CODE-HB) that recruits and repurposes the inherent B cell somatic hypermutation (SHM) mechanisms to rapidly evolve proteins is described. This approach uses stable, non-immunoglobulin loci within the genomes of human B cell lines for integration of a heterologous gene, such as a gene encoding an antibody or antibody fragment. A B-cell surface display platform for displaying fragment antigen binding domains (Fab) of antibodies is also described, which adapts the CODE-HB platform to rapidly evolve antibody fragments in a continuous manner. Plasmids and kits for carrying out these methods are also described.

The present disclosure provides a method for producing and expanding a population of B cells (e.g., human B cells for clinical application). This expanded population can be used to produce a B cell vaccine containing B cells that express 4-1BBL and can promote tumor cell death.

The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.

The application discloses a CD40 antibody or antigen binding fragment and application thereof. The CD40 antibody or antigen binding fragment has strong binding capacity with hCD40, can activate a CD40 / CD40L signal transduction pathway and downstream regulation signals thereof, can induce human B cell activation and significantly up-regulate CD95 protein expression, can promote B cell proliferation, can induce human PBMC-derived iDC cell activation and secrete a cytokine IL-12. The CD40 antibody or antigen binding fragment does not have ADCC effect, ADCP effect and CDC effect, can significantly reduce tumor volume / weight without affecting mouse body weight, prolong the survival time of mice, has good drug metabolism kinetics, and can be used for detecting hCD40 expression level and treating tumors.

Provided are compositions and methods that relate to therapy of B cell diseases and include discovery of novel molecular heterogeneity of the signaling component (i.e., CD79) of human B cell antigen receptor (BCR). The method includes co-administering antibodies or antigen binding fragments thereof that specifically bind CD79a and CD79b to provide synergistic therapy of B cell tumors. The method may further include administering an antibody that specifically binds to an immune checkpoint molecule, such as programmed cell death protein 1 (PD-1).

The present disclosure provides antibodies, and fragments thereof, having specificity for human B cell maturation antigen, pharmaceutical compositions thereof, and uses thereof. Also provided are chimeric antigen receptors (CARs) comprising such antibodies or antibody fragments, genetically-modified cells comprising such CARs, pharmaceutical compositions comprising such cells, methods for making such cells, and methods of using such cells for the treatment of disorders and diseases, such as cancer.